The 36-month beta value for ARQT is also noteworthy at 1.20. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ARQT is 102.89M, and at present, short sellers hold a 26.98% of that float. The average trading volume of ARQT on November 20, 2024 was 2.04M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ARQT) stock’s latest price update
The stock of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has increased by 7.00 when compared to last closing price of 9.43.Despite this, the company has seen a loss of -1.56% in its stock price over the last five trading days. zacks.com reported 2024-11-19 that Arcutis Biotherapeutics (ARQT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
ARQT’s Market Performance
Arcutis Biotherapeutics Inc (ARQT) has experienced a -1.56% fall in stock performance for the past week, with a 21.42% rise in the past month, and a 20.98% rise in the past quarter. The volatility ratio for the week is 8.12%, and the volatility levels for the past 30 days are at 6.75% for ARQT. The simple moving average for the past 20 days is 7.66% for ARQT’s stock, with a 6.80% simple moving average for the past 200 days.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with Jefferies repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to Jefferies is $15 based on the research report published on August 28, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $8, previously predicting the price at $4. The rating they have provided for ARQT stocks is “Buy” according to the report published on January 03rd, 2024.
Mizuho gave a rating of “Neutral” to ARQT, setting the target price at $4 in the report published on October 26th of the previous year.
ARQT Trading at 5.30% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.39% of loss for the given period.
Volatility was left at 6.75%, however, over the last 30 days, the volatility rate increased by 8.12%, as shares surge +20.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.18% lower at present.
During the last 5 trading sessions, ARQT fell by -1.56%, which changed the moving average for the period of 200-days by +67.61% in comparison to the 20-day moving average, which settled at $9.37. In addition, Arcutis Biotherapeutics Inc saw 212.38% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Matsuda Masaru, who sale 1,775 shares at the price of $9.68 back on Nov 19 ’24. After this action, Matsuda Masaru now owns 181,373 shares of Arcutis Biotherapeutics Inc, valued at $17,190 using the latest closing price.
Matsuda Masaru, the Officer of Arcutis Biotherapeutics Inc, proposed sale 1,775 shares at $9.68 during a trade that took place back on Nov 19 ’24, which means that Matsuda Masaru is holding shares at $17,190 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -1.31 for the present operating margin
- 0.89 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -1.41. The total capital return value is set at -0.69. Equity return is now at value -192.31, with -53.55 for asset returns.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -0.82. The debt to equity ratio resting at 1.31. The interest coverage ratio of the stock is -6.19.
Currently, EBITDA for the company is -227.43 million with net debt to EBITDA at -0.45. When we switch over and look at the enterprise to sales, we see a ratio of 9.04. The receivables turnover for the company is 2.31for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.46.
Conclusion
In summary, Arcutis Biotherapeutics Inc (ARQT) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
